Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
Guberina M, Poettgen C, Metzenmacher M, Wiesweg M, Schuler M, Aigner C, Ploenes T, Umutlu L, Gauler T, Darwiche K, Stamatis G, Theegarten D, Hautzel H, Jentzen W, Guberina N, Herrmann K, Eberhardt WEE, Stuschke M. Guberina M, et al. Among authors: eberhardt wee. J Nucl Med. 2021 May 20;62(12):1684-91. doi: 10.2967/jnumed.120.260646. Online ahead of print. J Nucl Med. 2021. PMID: 34016730 Free PMC article.
Surgery in stage III non-small-cell lung cancer.
Eberhardt WE, Stamatis G, Stuschke M. Eberhardt WE, et al. Lancet. 2009 Aug 1;374(9687):359-60. doi: 10.1016/S0140-6736(09)61026-6. Epub 2009 Jul 24. Lancet. 2009. PMID: 19632715 No abstract available.
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
Trarbach T, Schultheis B, Gauler TC, Schneider V, Strumberg D, Eberhardt WE, Le Scouiller S, Marotti M, Brown KH, Drevs J. Trarbach T, et al. Invest New Drugs. 2012 Oct;30(5):1962-71. doi: 10.1007/s10637-011-9754-x. Epub 2011 Oct 12. Invest New Drugs. 2012. PMID: 21989836 Clinical Trial.
Multimodal treatment of non-small-cell lung cancer.
Eberhardt WE, Stuschke M. Eberhardt WE, et al. Lancet. 2015 Sep 12;386(9998):1018-20. doi: 10.1016/S0140-6736(15)61083-2. Epub 2015 Aug 11. Lancet. 2015. PMID: 26275734 No abstract available.
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, Kasper S, Theegarten D, Hense J, Hager T, Darwiche K, Oezkan F, Aigner C, Welter S, Kühl H, Stuschke M, Schmid KW, Schuler M. Wiesweg M, et al. Among authors: eberhardt wee. J Thorac Oncol. 2017 Jan;12(1):54-64. doi: 10.1016/j.jtho.2016.08.137. Epub 2016 Aug 27. J Thorac Oncol. 2017. PMID: 27575422 Free article.
107 results